Quick Answer
GENMAB A/S reported R&D Expense of $1.61 billion for fiscal year 2025.
GENMAB A/S R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $1.61B | +13.6% |
| 2024 | $1.41B | +27.7% |
| 2023 | $1.11B | -53.6% |
| 2019 | $2.39B | +66.7% |
| 2018 | $1.43B | +63.7% |
| 2017 | $874.00M | — |
- GENMAB A/S showed an increase of +13.6% in R&D Expense compared to the prior fiscal year.
- Over the 2017–2025 period, GENMAB A/S’s r&d expense has grown by 83.8% (from $874.00 million to $1.61 billion).
- The most recent figure is from GENMAB A/S’s fiscal year 2025 report (Form 20-F), filed with the SEC on February 17, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: